drugset
drugset / Trial / NCT03895684

Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors

NCT03895684 ↗

Phase 1 Completed 23 enrolled Salarius Pharmaceuticals, LLC
NaSingle-groupOpen-labelTreatment

Summary

Phase 1, open-label, non-randomized dose finding study of SP-2577 in patients with advanced solid tumors.

Timeline

Start
2019-06-25
Primary completion
2021-04-13
Completion
2021-04-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Seclidemstat Small molecule — Oral

Indications

cancer